← Human Trials & Peer-Reviewed Studies
Influence of lanreotide on uptake of (68)Ga-DOTATATE in patients with neuroendocrine tumours: a prospective intra-patient evaluation
Plain-language guide to PMID 30097670 (2019): clinical trial study of Somatostatin and Lanreotide.
Key Facts
- PMID
- 30097670
- Journal
- European journal of nuclear medicine and molecular imaging
- Year
- 2019
- Study type
- Clinical Trial
- Authors
- Aalbersberg EA et al. (7 authors)
- DOI
- 10.1007/s00259-018-4117-x
What This Study Did, in Plain Language
What Was Tested
Researchers studied Somatostatin and Lanreotide in this clinical trial publication.
The aim of this study is to prospectively assess the effect of lanreotide use on the uptake of 68Ga-DOTATATE intra-individually 1 day prior to and 1 day post injection of lanreotide.
Paired T-tests were performed to determine the differences between the scans.
Why It Was Studied
Somatostatin receptor imaging with PET is the standard of care for patients with a neuroendocrine tumour (NET).
Since therapy and imaging with somatostatin analogues utilize the same receptor, current guidelines recommend withdrawing long-acting somatostatin analogues for 3-4 weeks prior to somatostatin receptor PET imaging.
Who Took Part
PubMed indexes the participants as middle-aged adults and older adults, both men and women.
Thirty-four patients with metastatic and/or unresectable NET and currently on lanreotide therapy for at least 4 months were included in the study.
In each patient 68Ga-DOTATATE uptake (SUVmax, mean, peak) was assessed in both tumour lesions and normal tissue.
How the Study Was Run
A 68Ga-DOTATATE PET/CT scan was performed on the day before and the day after lanreotide injection.
All scans were assessed by two blinded nuclear medicine physicians for visual analysis.
What Was Measured
The subject headings attached to it are Biological Transport, Neuroendocrine Tumors, Organometallic Compounds, Peptides, Cyclic, Positron Emission Tomography Computed Tomography, Receptors, Somatostatin and Somatostatin.
The authors tagged it with the keywords 68Ga-DOTATATE, Lanreotide, Neuroendocrine Tumours and PET/CT.
What This Means in Plain Language
This is a clinical trial of Somatostatin and Lanreotide.
Results are reported in around 6 sentences of the abstract; we leave them to the paper itself rather than summarise them.
The publication is from 2019 (European journal of nuclear medicine and molecular imaging), a journal based in Germany.
More context: the Somatostatin compound page and the Lanreotide compound page, all human trials.
Our Notes on the Compounds
Somatostatin: A 14-amino-acid hormone that switches off the release of several other hormones, including growth hormone and insulin.
Lanreotide: A long-acting 8-amino-acid somatostatin analog (Somatuline Depot) in the same class as octreotide.
Related Pages
Source: PubMed record. This explanation is written by PeptideWhiz from the public record. For research and education only. Not medical advice; no dosing information is given.